1. Home
  2. IPSC vs NEPH Comparison

IPSC vs NEPH Comparison

Compare IPSC & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPSC
  • NEPH
  • Stock Information
  • Founded
  • IPSC 2019
  • NEPH 1997
  • Country
  • IPSC United States
  • NEPH United States
  • Employees
  • IPSC N/A
  • NEPH N/A
  • Industry
  • IPSC Medicinal Chemicals and Botanical Products
  • NEPH Medical/Dental Instruments
  • Sector
  • IPSC Health Care
  • NEPH Health Care
  • Exchange
  • IPSC Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • IPSC 42.2M
  • NEPH 42.6M
  • IPO Year
  • IPSC 2021
  • NEPH 2004
  • Fundamental
  • Price
  • IPSC $0.49
  • NEPH $3.73
  • Analyst Decision
  • IPSC Strong Buy
  • NEPH Strong Buy
  • Analyst Count
  • IPSC 5
  • NEPH 2
  • Target Price
  • IPSC $3.33
  • NEPH $5.50
  • AVG Volume (30 Days)
  • IPSC 698.6K
  • NEPH 56.2K
  • Earning Date
  • IPSC 08-14-2025
  • NEPH 08-07-2025
  • Dividend Yield
  • IPSC N/A
  • NEPH N/A
  • EPS Growth
  • IPSC N/A
  • NEPH N/A
  • EPS
  • IPSC N/A
  • NEPH 0.12
  • Revenue
  • IPSC $114,128,000.00
  • NEPH $16,684,000.00
  • Revenue This Year
  • IPSC $1,589.94
  • NEPH $24.38
  • Revenue Next Year
  • IPSC N/A
  • NEPH $5.60
  • P/E Ratio
  • IPSC N/A
  • NEPH $31.30
  • Revenue Growth
  • IPSC 5491.77
  • NEPH 21.16
  • 52 Week Low
  • IPSC $0.34
  • NEPH $1.36
  • 52 Week High
  • IPSC $1.86
  • NEPH $5.00
  • Technical
  • Relative Strength Index (RSI)
  • IPSC 37.35
  • NEPH 46.02
  • Support Level
  • IPSC $0.46
  • NEPH $4.01
  • Resistance Level
  • IPSC $0.55
  • NEPH $4.50
  • Average True Range (ATR)
  • IPSC 0.04
  • NEPH 0.35
  • MACD
  • IPSC -0.00
  • NEPH -0.03
  • Stochastic Oscillator
  • IPSC 25.00
  • NEPH 2.40

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: